Multidrug resistance: molecular mechanisms and clinical relevance.
about
Identification of a novel topoisomerase inhibitor effective in cells overexpressing drug efflux transportersOvercoming cisplatin resistance by mTOR inhibitor in lung cancer.The effect of ABCB1 polymorphisms on the outcome of breast cancer treatmentStructural basis for gating mechanisms of a eukaryotic P-glycoprotein homolog.Effect of P-glycoprotein on flavopiridol sensitivityDrug resistance in natural isolates of Leishmania donovani s.l. promastigotes is dependent of Pgp170 expressionThe reversal effects of 3-bromopyruvate on multidrug resistance in vitro and in vivo derived from human breast MCF-7/ADR cellsEvaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial dataIncreased p38-MAPK is responsible for chemotherapy resistance in human gastric cancer cells.Effects of the multidrug resistance-1 gene on drug resistance in primary immune thrombocytopenia.TTFields alone and in combination with chemotherapeutic agents effectively reduce the viability of MDR cell sub-lines that over-express ABC transportersSpecific antioxidant compounds differentially modulate cytotoxic activity of doxorubicin and cisplatin: in vitro and in vivo study.P-glycoprotein and drug therapy in organ transplantation.Interaction of extracellular domain 2 of the human retina-specific ATP-binding cassette transporter (ABCA4) with all-trans-retinalFunctional expression and localization of P-glycoprotein at the blood brain barrier.New positron emission tomography tracer [(11)C]carvedilol reveals P-glycoprotein modulation kinetics.Drug resistance in brain diseases and the role of drug efflux transporters.Can multidrug resistance mechanisms be modified?Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kappaB signaling.The enhanced anti-cancer effect of hexenyl ester of 5-aminolaevulinic acid photodynamic therapy in adriamycin-resistant compared to non-resistant breast cancer cells.Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation.Synthesis and discovery of water-soluble microtubule targeting agents that bind to the colchicine site on tubulin and circumvent Pgp mediated resistanceClitocine targets Mcl-1 to induce drug-resistant human cancer cell apoptosis in vitro and tumor growth inhibition in vivo.Therapeutic ultrasound: its application in drug delivery.Xenobiotic transporters: another protective mechanism for chemicals.N,N-diethyl-2-[4-(phenylmethyl) phenoxy] ethanamine (DPPE; tesmilifene), a chemopotentiating agent with hormetic effects on DNA synthesis in vitro, may improve survival in patients with metastatic breast cancer.Screening for phenotype selective activity in multidrug resistant cells identifies a novel tubulin active agent insensitive to common forms of cancer drug resistance.Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models.Reversal of multidrug resistance by 5,5'-dimethoxylariciresinol-4-O-β-D-glucoside in doxorubicin-resistant human leukemia K562/DOX.Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines.2-Amino-4-methyl-5-phenylethyl substituted-7-N-benzyl-pyrrolo[2,3-d]pyrimidines as novel antitumor antimitotic agents that also reverse tumor resistance.Genome-wide molecular characterization of central nervous system primitive neuroectodermal tumor and pineoblastoma.Synthesis and biological activities of (R)- and (S)-N-(4-Methoxyphenyl)-N,2,6-trimethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-aminium chloride as potent cytotoxic antitubulin agents.Development of a novel class of tubulin inhibitor from desmosdumotin B with a hydroxylated bicyclic B-ringA promising strategy for overcoming MDR in tumor by magnetic iron oxide nanoparticles co-loaded with daunorubicin and 5-bromotetrandrin.Comparative genomics and adaptive selection of the ATP-binding-cassette gene family in caenorhabditis species.Overexpression of Bcl-x(L) promotes chemotherapy resistance of mammary tumors in a syngeneic mouse model.Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCG2: therapeutic implications.Cytotoxic agents directed to peptide hormone receptors: defining the requirements for a successful drug.In situ biochemical demonstration that P-glycoprotein is a drug efflux pump with broad specificity.
P2860
Q24648348-DC845F81-F20D-4045-BE62-87A5C88578DDQ24815638-02DDA067-D7FD-4660-AB1A-C2D151A6E81DQ26749954-3B01BAEC-7CB9-473E-8C32-0D718CBCA6CCQ27681970-595C3A1F-5FD4-4773-9B80-1D08C5D31E09Q28365275-0DD2BD95-B1D5-4DD1-B36F-4FAA0C375707Q28533820-A3ADD06A-F182-48D9-AA3B-9521F1F56113Q28544747-BA4BE936-D0C8-49DD-8C3A-4D7B99F99D0AQ33388617-6907AEB1-BAFA-4362-A6C9-F19DCDFBED38Q33394070-0F2EF956-76F0-4311-848E-D840B0E967B0Q33432692-207507E3-3D54-4B43-9AA1-B08873D8255CQ33584376-BA059CE8-4044-4B4A-A377-9DFC4DA779B0Q33725416-082910ED-259B-4F33-B136-28F2AEAA5D16Q33749785-84B22A54-5A1B-4EF8-A4F9-F787C8A7E99EQ33911373-6B42D387-4767-4C1E-8B38-50FFDAFB6A63Q33960099-C58BB182-EE6A-4B0C-9ED1-0B83D22FF06CQ33987752-26774465-461A-49E4-8525-F014B172B7DDQ33988704-B23A9E2A-A6B4-425C-A81B-EA80AC7AF6FEQ34022485-A9F5618B-F8CA-4AAD-9809-B0F65EEEDC75Q34124356-B92FB298-9FBA-4581-A2D4-BC11D5A65B60Q34128145-5325D03B-C1B5-4FFC-92C7-74E58841205EQ34303346-97671B0D-A4CC-4AB3-B1DA-DFB73098B038Q34336551-7BD36998-4F8B-44F9-A549-F6A11DDB88A2Q34406244-5CE5A649-D374-4628-95A2-04EED8C59DFFQ34540070-87B056A8-2259-474D-80BE-6F534EA1EDA0Q34590550-14827F2A-2E6A-49B3-A9FB-F4197396DF8CQ34778630-3E976A7E-EE9B-4B83-B703-58A8BFF5B11FQ34898761-32128F1F-8194-4F0A-8D25-F9BA754B44FCQ35005087-72A72E2D-C272-4AE1-9330-2CAD2BDB791EQ35069074-228E5528-5D5C-4531-B52A-3C1DD2AEF4F9Q35076110-64B9D908-D84E-4976-94FA-BCE37DEFF350Q35110635-8E4813B6-3AF9-4DA7-A405-0DA345276C1CQ35133413-E34B524F-394B-479E-8F30-88BF3950DC7FQ35253350-427BA837-7DED-457D-BFFD-E5370677157DQ35384689-006CFC88-7D23-4E24-A809-988B98A720A0Q35547203-FE8C9F32-B7D0-4F43-A5D0-FC6E73095EDDQ35730057-9D86ADD6-2646-45D8-9FB4-DDB7A1768951Q35788016-2AF78732-8019-4F5F-8BE4-A7A14DB8442BQ36301589-131837E7-B891-4F51-A348-19486CB35910Q36312379-C8574DB4-A091-452F-BA27-C94EDC2CA3B2Q36326998-82DBAA17-7BCE-49E1-89B8-8F7F7E9B8D51
P2860
Multidrug resistance: molecular mechanisms and clinical relevance.
description
1997 nî lūn-bûn
@nan
1997 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Multidrug resistance: molecular mechanisms and clinical relevance.
@ast
Multidrug resistance: molecular mechanisms and clinical relevance.
@en
Multidrug resistance: molecular mechanisms and clinical relevance.
@nl
type
label
Multidrug resistance: molecular mechanisms and clinical relevance.
@ast
Multidrug resistance: molecular mechanisms and clinical relevance.
@en
Multidrug resistance: molecular mechanisms and clinical relevance.
@nl
prefLabel
Multidrug resistance: molecular mechanisms and clinical relevance.
@ast
Multidrug resistance: molecular mechanisms and clinical relevance.
@en
Multidrug resistance: molecular mechanisms and clinical relevance.
@nl
P356
P1476
Multidrug resistance: molecular mechanisms and clinical relevance.
@en
P2093
P2888
P356
10.1007/S002800051053
P478
P577
1997-01-01T00:00:00Z
P6179
1022009924